53 related articles for article (PubMed ID: 9376277)
1. Hammerhead ribozymes selectively suppress mutant type I collagen mRNA in osteogenesis imperfecta fibroblasts.
Dawson PA; Marini JC
Nucleic Acids Res; 2000 Oct; 28(20):4013-20. PubMed ID: 11024182
[TBL] [Abstract][Full Text] [Related]
2. A novel functional genomics approach identifies mTERT as a suppressor of fibroblast transformation.
Li QX; Robbins JM; Welch PJ; Wong-Staal F; Barber JR
Nucleic Acids Res; 2000 Jul; 28(13):2605-12. PubMed ID: 10871412
[TBL] [Abstract][Full Text] [Related]
3. Enhanced ovarian cancer tumorigenesis and metastasis by the macrophage colony-stimulating factor.
Toy EP; Azodi M; Folk NL; Zito CM; Zeiss CJ; Chambers SK
Neoplasia; 2009 Feb; 11(2):136-44. PubMed ID: 19177198
[TBL] [Abstract][Full Text] [Related]
4. Development of antithrombotic miniribozymes that target peripheral tryptophan hydroxylase.
Peter JU; Alenina N; Bader M; Walther DJ
Mol Cell Biochem; 2007 Jan; 295(1-2):205-15. PubMed ID: 16924415
[TBL] [Abstract][Full Text] [Related]
5. Genetic factors in ovarian carcinoma.
Li AJ; Karlan BY
Curr Oncol Rep; 2001 Jan; 3(1):27-32. PubMed ID: 11123866
[TBL] [Abstract][Full Text] [Related]
6. Kinase inhibitors in cancer therapy: a look ahead.
Sedlacek HH
Drugs; 2000 Mar; 59(3):435-76. PubMed ID: 10776829
[TBL] [Abstract][Full Text] [Related]
7. Hammerhead ribozymes to modulate telomerase activity of endometrial carcinoma cells.
Yokoyama Y; Wan X; Shinohara A; Takahashi Y; Tamaya T
Hum Cell; 2001 Sep; 14(3):223-31. PubMed ID: 11774741
[TBL] [Abstract][Full Text] [Related]
8. Modulation of c-fms proto-oncogene in an ovarian carcinoma cell line by a hammerhead ribozyme.
Yokoyama Y; Morishita S; Takahashi Y; Hashimoto M; Tamaya T
Br J Cancer; 1997; 76(8):977-82. PubMed ID: 9376277
[TBL] [Abstract][Full Text] [Related]
9. Expression of c-fms proto-oncogene product by ovarian cancer cell lines with effects of macrophage colony-stimulating factor on proliferation.
Suzuki M; Sekiguchi I; Ohwada M; Sato I; Matsui T; Tanabe T; Hashimoto S; Yamada M
Oncology; 1996; 53(2):99-103. PubMed ID: 8604248
[TBL] [Abstract][Full Text] [Related]
10. Selection of a high activity c-erbB-2 ribozyme using a fusion gene of c-erbB-2 and the enhanced green fluorescent protein.
Wiechen K; Zimmer C; Dietel M
Cancer Gene Ther; 1998; 5(1):45-51. PubMed ID: 9476966
[TBL] [Abstract][Full Text] [Related]
11. Reversion of multidrug resistance in the P-glycoprotein-positive human pancreatic cell line (EPP85-181RDB) by introduction of a hammerhead ribozyme.
Holm PS; Scanlon KJ; Dietel M
Br J Cancer; 1994 Aug; 70(2):239-43. PubMed ID: 7914421
[TBL] [Abstract][Full Text] [Related]
12. Transforming mechanism of the feline sarcoma virus encoded v-fms oncogene product.
Tamura T; Hadwiger-Fangmeier A; Simon E; Smola U; Geschwill H; Schütz B; Trouliaris S; Boscheck B; Niemann H; Bauer H
Behring Inst Mitt; 1991 Jul; (89):93-9. PubMed ID: 1834054
[TBL] [Abstract][Full Text] [Related]
13. Development of a hammerhead ribozyme against bcl-2. I. Preliminary evaluation of a potential gene therapeutic agent for hormone-refractory human prostate cancer.
Dorai T; Olsson CA; Katz AE; Buttyan R
Prostate; 1997 Sep; 32(4):246-58. PubMed ID: 9288183
[TBL] [Abstract][Full Text] [Related]
14. Cell growth regulation in epithelial ovarian cancer.
Bast RC; Boyer CM; Jacobs I; Xu FJ; Wu S; Wiener J; Kohler M; Berchuck A
Cancer; 1993 Feb; 71(4 Suppl):1597-601. PubMed ID: 8431895
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
